Clinical Trials Logo

Type2 Diabetes Mellitus clinical trials

View clinical trials related to Type2 Diabetes Mellitus.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06464900 Not yet recruiting - Clinical trials for Type2 Diabetes Mellitus

Effects of a Health Intervention on Fear of Hypoglycemia : a Randomized Controlled Study

Start date: June 2024
Phase: N/A
Study type: Interventional

To examine the effects of a health Education Intervention based on the Behaviour Change Wheel (BCW) theory on fear of hypoglycemia and relevant outcomes of type 2 diabetic patients.

NCT ID: NCT06257966 Not yet recruiting - Clinical trials for Type2 Diabetes Mellitus

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

The aim of the study is to compare the efficacy and safety of two JY09 doses versus dulaglutide as add-on therapy to metformin in participants with type 2 diabetes mellitus (T2DM)

NCT ID: NCT05539066 Not yet recruiting - Health Behavior Clinical Trials

AI Health Assistant and Type 2 Diabetes

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

The developed health assistant has the functions of intelligent analysis of health data inside and outside the hospital, health reminder, etc. The advantages of AI health assistant management group compared with conventional management group in terms of comprehensive compliance rate, metabolic index level, hypoglycemia incidence rate was further studied.

NCT ID: NCT04287387 Not yet recruiting - Clinical trials for Type2 Diabetes Mellitus

Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents

Start date: March 2, 2020
Phase: Phase 4
Study type: Interventional

Intestinal microflora refers to the trillions of microorganisms living in our gut, which is considered as an independent endocrine organ of human body. Intestinal microbiota plays a very important role in human health. The composition of human intestinal microbiota is affected by a variety of factors, including age, living region, eating habits, nutrition, probiotics, antibiotics and so on. It is found that the imbalance of intestinal microbiota is closely related to the occurrence and development of metabolic diseases including type 2 diabetes mellitus (T2DM). There are great differences in the structure and function of intestinal microbiota between healthy people and T2DM patients, and recently changes of intestinal microbiota have been observed in pre-diabetes. In recent years, it has been found that some commonly used hypoglycemic drugs may regulate and improve the imbalance of intestinal flora of T2DM patients, including metformin, α - glucosidase inhibitor, and Glucagon-like peptide-1(GLP-1) receptor agonist, which have a positive impact on the short chain fatty acid (SCFAs) producing bacteria. However, on the one hand, subjects of those studies were mostly western population and there were just a few studies on the influence of anti-diabetic drug on human gut microbiota in Chinese population, on the other hand, the study of influence of Dipeptidyl peptidase-4(DPP-4) inhibitors, sulfonylureas, sodium-dependent glucose transporters-2(SGLT-2) inhibitors or thiazolidinediones on intestinal microbiota is rare or even absent. This study aims to explore the effect of different hypoglycemic drugs on intestinal flora and find the potential intestinal target of drug action in Chinese population.

NCT ID: NCT04246190 Not yet recruiting - Clinical trials for Type2 Diabetes Mellitus

A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396

Start date: February 24, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics and safety of CKD-396.

NCT ID: NCT04223895 Not yet recruiting - Clinical trials for Type2 Diabetes Mellitus

A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers

Start date: February 1, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics and Safety/Tolerability of CKD-386

NCT ID: NCT04221360 Not yet recruiting - Clinical trials for Type2 Diabetes Mellitus

A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-375

Start date: January 29, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of CKD-375.

NCT ID: NCT04082091 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention

SELECT
Start date: September 2019
Phase:
Study type: Observational

We will evaluate an e_Prescription intervention can be integrated into an electronic screening program, which together exploit: (i) reach - the adult population has 100% mobile phone ownership and 92% internet national coverage; and (ii) behavioral change - the intervention can teach verbally and visually, thus bypassing literacy challenges, to allow simple, low-cost, repetition messaging for habit reinforcement. Uptake of the program through the various stages will be evaluated in ~2000 adults of a large representative suburban district of Karachi: As well as before-and-after physiological measures, including blood pressure (BP) and blood glucose, a random sample of 30-40 participants will be invited for interview to assess success and failure of the program. This is a pragmatic feasibility intervention implementation study.

NCT ID: NCT03513055 Not yet recruiting - Clinical trials for Type2 Diabetes Mellitus

Influence of Injection Technique of Premixed Insulin on Glucose Excursion in Type 2 Diabetes Mellitus

Start date: May 7, 2018
Phase: N/A
Study type: Interventional

To compare patients and nurses using insulin pen injector to inject premixed insulin respectively, using continuous glucose monitoring system to evaluate the glucose excursion in the two sets, study the relationship between glucose excursion and inject technique in type 2 diabetes mellitus.

NCT ID: NCT03470415 Not yet recruiting - Clinical trials for Type2 Diabetes Mellitus

Relation of Epicardial Fat and Diabetic Nephropathy in Egyptian Patients

Start date: May 2018
Phase:
Study type: Observational [Patient Registry]

The heart and vessels are surrounded by layers of adipose tissue, which is a complex organ composed of adipocytes, stromal cells, macrophages, and a neuronal network, all nourished by a rich microcirculation. The layers of adipose tissue surrounding the heart can be subdivided into intra- and extra-pericardial fat. Their thicknesses and volumes can be quantified by echocardiography and computed tomography or magnetic resonance imaging, respectively. The term extrapericardial fat defines thoracic adipose tissue external to the parietal pericardium. It originates from primitive thoracic mesenchymal cells and thus derives its blood supply from noncoronary sources. Intrapericardial fat is further subdivided into epicardial and pericardial fat. Anatomically, epicardial and pericardial adipose tissues are clearly different. Epicardial fat is located between the outer wall of the myocardium and the visceral layer of pericardium.